| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10908907 | Leukemia Research | 2013 | 6 Pages |
Abstract
Moxetumomab pasudotox (HA22) is an immunotoxin with an anti-CD22 Fv fused to a portion of Pseudomonas exotoxin A that kills CD22 expressing ALL cells. HA22 produced significant responses in some cases of ALL. To understand how to increase response rate, we isolated HA22-resistant KOPN-8 cells and found that HA22 cannot inactivate elongation factor-2 (EF2) due to low levels of DPH1 RNA and protein. Resistance was associated with methylation of the CpG island in the DPH1 promoter. 5-Azacytidine prevented resistance and methylation of the CpG residues and merits evaluation to determine if it can increase the efficacy of HA22 in ALL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xiaobo Hu, Hui Wei, Laiman Xiang, Oleg Chertov, Alan S. Wayne, Tapan K. Bera, Ira Pastan,